MODERN APPROACHES TO TREATMENT OF RENAL CELL CARCINOMA ACCORDING TO THE MATERIALS OF THE VII INTERNATIONAL CONFERENCE OF RENAL CANCER EXPERTS (CORE, 2016)
- Authors: Sayapina M.S1, Nosov D.A1
-
Affiliations:
- FSBIS "RORC n.a. N.N. Blokhin" of RMH
- Issue: No 8 (2016)
- Pages: 10-13
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/288906
- ID: 288906
Cite item
Open Access
Access granted
Abstract
The review presents information about the VII Annual International Conference of Renal Cancer Experts (CORE), which highlights the latest results from the world's leading research institutes and clinics in the field of treatment of patients with renal cell carcinoma. This year, CORE was organized under the auspices of Novartis and was held in Geneva (Switzerland) from 2nd April 2016 to 3rd April 2016.
Full Text
About the authors
M. S Sayapina
FSBIS "RORC n.a. N.N. Blokhin" of RMH
Email: maria.sayapina@mail.ru
postgraduate student of the Department of Clinical Pharmacology and Chemotherapy Moscow
D. A Nosov
FSBIS "RORC n.a. N.N. Blokhin" of RMHDepartment of Clinical Pharmacology and Chemotherapy Moscow
References
- Atkins M.B., Gupta S., Choueiri T.K., McDermott D.F., Puzanov I., Taraz J., Keefe S., Rosbrook B, Chakrabarti D., Plimack E.R. J. Immunother. Cancer. 2015;3(Suppl 2):P353.
- The Cancer Genome Atlas Research Investigators: Comprehensive molecular characterization of papillary renal cell carcinoma. N. Engl. J. Med. 2015;499:43-9.
- Pal S.K., Choueiri T.K, Wang K., Khaira D., Karam J.A., Van Allen E., Palma N.A., Stein M.N., Johnson A, Squillace R., Elvin J.A., Chmielecki J., Yelensky R., Yakirevich E., Lipson D., Lin D.I., Miller V.A., Stephens P.J., Ali S.M., Ross J.S. Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. Eur. Urol. 2015 Jul 3. pii: S0302-2838(15)00522-9.
- Hsieh J., Chen D., Wang P., et al. Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): Results from RECORD-3. J. Clin. Oncol. 2015;33(suppl):abstr 4509.
- Fay A.P., Kwiatkowski D.J., Gray K.P., Thorner A., Rini B.I., Agarwal N., Ho J.H., Song J., Barrios P.M., Albiges L.,Va nAllen E. M., Krajewski K. M., Porta C., Pal S.K., Bellmunt J., McDermott D.F., Chin Heng D.Y., Signoretti S,. Choueiri T.K. ASCO 2015:abstr. 4519.
- Voss M.H., et al. Mutation burden and tumor neoantigens in RCC patients (pts) treated with nivolumab. J. Clin. Oncol. 2016;34(Suppl 2S):abstr. 514.
- Zhou L., Liu X-D., Sun M., Zhang X., German P., Bai S., Ding Z., Tannir N., Wood C.G., Matin S.F., KaramJ.A.,TamboliP.,SircarK.,RaoP.,RankinE.B., Laird D.A., Hoang A.G., Walker C.L., Giaccia A.J., Jonasch E. Cabozantinib overcomes antiangioenic therapy resistance. Oncogene. 2015:1-11.
- Voss M.H., Plimack E.R., Rini B.I., Atkins M.B., Alter R., Bhatt R.S., Beck J.T., Pappas K.M., Wilson D., Zhang X., Sherman M.L., Pandya S.S. J Clin. Oncol. 2015;33(Suppl 7):abstr. 407.
- Rini B.I., Tomita Y., Melichar B., et al. Overall survival analysis from a randomized phase II study of axitinib with or without dose titration for first-line metastatic renal cell carcinoma. J. Clin. Oncol. 2015;33(Suppl):abstr. 4545.
- De Meerleer G., Khoo V., Escudier B., Joniau S., Bossi A., Ost P., Briganti A., Fonteyne V., Van Vulpen M., Lumen N., Spahn M., Mareel M. Radiotherapy for renal-cell carcinoma. Lancet Oncol. 2014;15(4):e170-77.
- Fokas E., Henzel M., Hamm K., Surber G., Kleinert G., Engenhart-Cabillic R. Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery?: analysis of 88 patients. Strahlenther. Onkol. 2010; 186:210-77.
- Rades D., Panzner A., Dziggel L., Haatanen T., Lohynska R., Schild S.E. Dose-escalation of whole-brain radiotherapy for brain metastasis in patients with a favorable survival prognosis. Cancer. 2012;118:3852-59.
- Zelefsky M.J. Greco C., Motzer R., Magsanoc J.M., Pei X, Lovelock M., Mechalakos J, Zatcky J, Fuks Z., Yamada Y. Tumor control outcomes after hypofractionated and single-dose stereo tactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2012;82(5):1744-48.
Supplementary files
